Dr. Gerard S. Goh and Dr. Thodur Vasudevan of the Alfred Hospital in Melbourne, Australia, completed the stent implant. The company says it introduces a “revolutionary advancement” in the mechanics, durability and drug delivery of peripheral drug-eluting stents.
Tel Aviv, Israel-based Medinol designed ChampioNIR to improve both patient outcomes and procedural success. It features a first-of-its-kind hybrid mechanical design that has radial support provided by the metallic component of the stent. A bioresorbable polymeric mesh provides longitudinal structure for flexibility and durability in challenging anatomies.
ChampioNIR has a unique drug-elution paradigm that releases the drug from the entire cylindrical area of the stent. This drastically reduces diffusion distances and allows for the therapeutic dosing of a large peripheral vessel with a limus drug for an extended period of time.
Medinol has its CHAMPIONSHIP first-in-human study underway in Australia and the U.S. It plans to enroll a total of 30 patients across seven sites in those countries.
“Medinol is excited to bring to clinical practice the culmination of years of research and development into novel stent designs, tailor-made for unmet clinical challenges in vascular interventions,” said Dr. Yoram Richter, CEO of Medinol.
